Table 3.

Detection of new (unknown ADRs) among 154 patients on Target-Vig

	Follow up (months)	Observed
	Median (IQR)	N	% (95% CI)
Bevacizumab	6.7 (3.9–7.8)
Hypomagnesaemia		6	12.2 (3.1–21.4)
Cetuximab	3.4 (2.6–5.2)
Neutropenia		3	25.0 (0.5–49.5)
Lenalidomide	6.7 (4.2–9.3)
Hyperglycaemia		7	50.0 (23.8–76.2)
Hypercholesterolaemia		4	28.6 (4.9–52.2)
Sorafenib	4.9 (2.9–11.5)
Hyperglycaemia		5	25.0 (6.0–44.0)
Hypercholesterolaemia		3	15.0 (0.0–30.6)
Hypertriglyceridaemia		2	10.0 (0.0–23.1)

CI Confidence Interval, IQR Interquartile Range